The global Genital Warts Treatment Market is estimated to be valued at US$ 1785.61 Mn in 2023 and is expected to exhibit a CAGR of 4.7% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Genital warts, also known as human papillomavirus (HPV) infection, are common sexually transmitted infections that are caused by certain types of human papillomavirus (HPV). They may appear as small bumps or groups of bumps in the genital area of males and females. Genital warts can cause physical discomfort or psychological distress. Imiquimod, podophyllotoxin, and sinecatechins are some common medications used in the treatment of genital warts.
Market key trends:
The prevalence of HPV infection is increasing significantly and majority of the sexually active individuals get exposed to HPV at some point in their lifetime. As per CDC, about 14 million people in the U.S. get newly infected with HPV each year. Increasing awareness about the hazards of untreated sexually transmitted infections including genital warts is prompting more people to opt for their medical treatment. Moreover, development of newer treatment options like topical creams and lotions that can be self-administered by patients themselves is also fueling the demand. However, high cost of branded genital wart treatment medications and social stigma associated with genital warts, deter many patients from seeking timely treatment.
Segment Analysis
The global genital warts treatment market is segmented based on type, treatment, end-user, and region. Based on type, the market is segmented into external genital warts and internal genital warts. The external genital warts segment currently dominates the market as it is more commonly diagnosed than internal genital warts. By treatment, the market is divided into topical therapies, cryotherapy, trichloroacetic acid/bichloroacetic acid, surgical procedures, and immunomodulators. Topical therapies hold the largest market share as they are the first line of treatment for genital warts and have fewer side effects than other therapies. On the basis of end-user, the market is bifurcated into hospitals, clinics, diagnostic centers, and research institutes. Hospitals account for the largest share due to the availability of advanced diagnostic and treatment facilities.
Key Takeaways
Content:
The global Genital Warts Treatment Market Growth is expected to witness high growth, exhibiting a CAGR of 4.7% over the forecast period, due to increasing prevalence of human papillomavirus (HPV) infections globally.
Regional analysis:
North America currently dominates the market and is expected to continue its dominance over the forecast period. This is attributed to growing awareness about STDs, availability of advanced treatment options, and favorable reimbursement policies in the region. Asia Pacific is anticipated to exhibit the fastest growth owing to rising healthcare expenditure, growing medical tourism industry, and increasing incidence of HPV infections.
Key players:
Key players operating in the genital warts treatment market are Sanofi S.A., AbbVie Inc., Perrigo Company PLC, 3M, Lee's Pharmaceutical Holdings Ltd, Cassiopea, Glenmark Pharmaceuticals, Bausch Health, and Novartis International AG. Sanofi S.A. holds the largest market share currently due to its broad product portfolio and global presence. AbbVie Inc. and Perrigo Company PLC hold significant shares as well due to their strong brand recognition and marketing strategies.
For more insights, read- https://www.ukwebwire.com/genital-warts-treatment-market-trends-size-and-share-analysis/
Comments
0 comment